Nomogram of age-specific anti-Müllerian hormone levels in healthy Egyptian females

Eman Ahmed El-Attar1*, Tamer A. Hosny2, Kiyoshi Ichihara3, Rania N. Bedair1, Ahmed Salah El-Din Tork1

1 Chemical Pathology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt, 2 Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Alexandria, Egypt, 3 Faculty of Health Sciences, Department of Clinical Laboratory Sciences, Yamaguchi University Graduate School of Medicine, Ube, Japan

* eman.elattar@alexu.edu.eg

Abstract

Background

Anti-Müllerian hormone (AMH) is an important determinant of ovarian reserve in fertility workups in many clinical settings. Thus, we investigated the age dependent decline in AMH specific to the Egyptian population and sought to establish an age dependent reference interval parametrically.

Methods

Serum samples were collected from 841 apparently healthy women. AMH was measured using an electro-chemiluminescent technique. Box-Cox power transformation was used to make the AMH distribution Gaussian for parametric derivation of reference intervals.

Results

Power of 0.4 was found optimal for Gaussian transformation of AMH reference values. We demonstrate the strong negative relation between circulating AMH and female age with Spearman’s correlation coefficient of $r_S = -0.528$. Age-specific reference interval was determined for every 5 years of age from 16 to 49, and nomogram was constructed by smoothing the lines connecting adjacent lower and upper reference limits.

Conclusion

The age-specific reference intervals and the age-AMH nomogram could be valuable in the clinical practice of in reproductive medicine. To our knowledge, this is the first study to confirm AMH levels in Egyptian females. We were able to explore age-related AMH levels specific to Egyptian females in the fertile age group and to treat skewed AMH data in a multi-step scheme using power transformation. Thus, a more accurate nomogram was constructed accommodating a profile delineated for a wide age range and a rescaled AMH axis improving its usability.
Introduction

The concept of ovarian reserve which reflects the quantity and quality of oocytes is an essential topic as assisted reproduction is gaining popularity over the years. Among markers of ovarian reserve, AMH has gained particular interest as it exhibits very low intra and inter cycle variability. AMH is clearly related to ovarian function as it is secreted by the granulosa cells of developing follicles until they reach a suitable size and differentiation state under the influence of pituitary FSH [1, 2]. Hence, serum AMH levels essentially reflect the ovarian follicular pool [3]. AMH was also found to be superior to antral follicular count and FSH levels in predicting menopause onset [4].

AMH is secreted by the ovary into circulation, hence AMH is measurable in serum. Interestingly, in women circulating AMH appears to be exclusively of ovarian origin. Following bilateral ovariectomy, AMH levels reach undetectable values within 3–5 days [5]. In clinical settings, the low inter- and intra-cycle variability in serum AMH levels permits random timing of AMH measurement during the menstrual cycle. In women, AMH levels seem to be unmodified under conditions in which endogenous gonadotrophin release is substantially diminished, such as during pregnancy, GnRH agonist and short-term oral contraceptive treatment. This indicates that non-cyclic, FSH-independent ovarian activity persists even when pituitary FSH secretion is suppressed [6].

Previous studies have reported important clinical features and utilities of serum AMH including decline with aging, a good correlation with oocyte yield in assisted reproduction, increased levels in polycystic ovarian syndrome, and decreased levels following ovarian surgery and toxic treatment. Recent studies, including meta-analysis studies and clinical trials together with the new generation AMH assays that enabled accurate measurement of very low serum concentrations, have yielded firm clinical interpretations of serum AMH in the past few years. [7–9]

Age-independent standardization of AMH values was suggested to compare ovarian reserves among women at different ages [7]. Validation of an age-related AMH nomogram will enable better clinical counseling concerning reproductive capacity [10]. We aim to define the decline in circulating AMH with age and develop and validate an age-related nomogram in Egyptian women.

Despite the strong association between AMH levels and age, age-adjusted reference intervals have not been introduced to clinical practice. This could be a new approach to clinical judgement of fertility & ovarian reserve in different age groups. To our knowledge, this is the first study to explore age-related AMH levels in Egyptian females.

Methodology

Patient cohort

From January 2018 to March 2019, 998 apparently healthy females attending the Alexandria University hospital laboratory for AMH analysis were recruited in this study. Written informed consents were obtained from all participating females. The Ethical Committee of Medical Research Institute, Alexandria University approved this work. All study procedures were performed in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments.

All participating females were asked to fill out a questionnaire form that included questions about age, childbearing, previous surgeries, history of infertility, and history of polycystic ovary syndrome (PCOS). Women who had conceived and bore children were considered to have proven fertility. We excluded females having medical history or other laboratory tests
suggestive of infertility or PCOS, previous ovarian surgeries, unexplained infertility or those having any endocrinological disorders. Participants were studied cases by case to exclude any unclear or missing data. Women who had visited infertility clinics and were informed of no pathology were included in the study. Cases of infertility were included only if the reason was male infertility. The study started with 998 females and funneled down to 841 females after excluding the above conditions. Thus, this study population represents a normal fertile Egyptian female population (Fig 1).

**AMH assay**

AMH assay was performed using electrochemiluminescence technology on cobas e 601 module, Roche using Elecsys AMH kit. Results were expressed in ng/mL. Intraassay and interassay coefficient of variation were 1.7% & 3.5%, respectively.

**Statistical analysis**

Data was collected, tabulated and patients with missing age or AMH values were excluded. The parametric method was used to calculate the AMH RI. Since the distribution of our AMH test results was non-Gaussian, with a great degree of positive skewness, we used power transformation based on the Box-Cox formula [11]

\[
X = \left(\frac{x^{p} - 1}{p}\right) \quad \text{when } p \neq 0.0
\]

\[
X = \log(x) \quad \text{when } p = 0.0
\]

**formula 1:** (The Box-Cox formula)

where \(x\) and \(X\) denote observed value before and after transformation, and the ‘\(p\)’ represents the power of the transformation.

The ‘\(p\)’ value was empirically determined by use of probability plot. The ‘\(p\)’ was changed stepwise from 1.0 to 0.0 with decrement of 0.1, and an optimal ‘\(p\)’ value (\(p_0\)) was determined as 0.4 that gave the longest linear segment in the probability plot (Fig 2).
To make a nomogram for age-specific reference intervals, the following procedure was used:

1. AMH dataset were power transformed using $p^0$ to approximate a Gaussian distribution.

2. A paired dataset with data size $N$ composed of age ($X_i$) and test result ($Y_i$) [$i = 1$ to $N$] were multiplied by $R$ times ($R = 10$) to inflate the size to $N \times R$. In this process of multiplication, a flat random value between $-2.0$ to $2.0$ was added to $X_i$ (age), and that between $-0.2$ and $0.2$ were added to $Y_i$ (AMH$_{0.4}$).

3. The dataset was then stratified by an age block of every 5 years, and block-wise summary statistics of mean ($M^T_k$) and SD ($SD^T_k$) were calculated. Then, the 95% confidence interval for the block ($k$) was derived as $M^T_k \pm 1.96 \times SD^T_k$ (or $LL^T = M^T_k - 1.96 \times SD^T_k$; $UL^T = M^T_k + 1.96 \times SD^T_k$), where LL and UL represent lower limit and upper limit of the RI, respectively.

4. Then, $LL^T$ and $UL^T$ were reverse transformed to obtain the LL and UL at the original scale.

5. The vertical data block by age was moved upwards by one year of age for calculating the summary statistics in a stepwise fashion.

**Fig 2. Confirmation of Gaussian transformation of AMH values by probability plot.** The vertical axis represents the cumulative frequency ($P\%$), transformed as $\log[(100 - P)/P]$. The horizontal axis represents AMH test results. This axis was transformed by use of Box–Cox formula using $p = 0.4$ as an optimal power. The linearity of the segment between 10 and 90% indicates successful Gaussian transformation by use of the formula.

https://doi.org/10.1371/journal.pone.0254858.g002
6. Curves connecting the summary statistics were smoothed using the Bezier curve function of Microsoft Power Point.

Results

The distributions of AMH among 841 apparently healthy Egyptian females are shown in Fig 3 without (left) and with transformation by setting \( p = 0.4 \) (right). The relationship of AMH and age was drawn, as shown Fig 4, without (left) and with power transformation of the Y-axis to fit the transformation (right). The degree of association between age and AMH calculated as Spearman’s correlation \( (r_S) \) was \(-0.528\).

The nomogram of age-related profile of median and 95% CI (LL and UL) of AMH was produced as shown in Fig 5 by the scheme described in the Methods. The age specific RIs that were determined in every 5 years of age from 16 to 49 are shown in Table 1. The scale of the AMH axis in our nomogram was also adjusted to fit our AMH power transformation, Thus, AMH reference interval for any age can be directly deduced from our nomogram (Fig 5).

Discussion

Serum AMH level is a marker of continuous non-cyclic growth of ovarian follicles. To date, the ovarian reserve of primordial follicles cannot be clinically assessed. We describe the relationship between AMH and age of Egyptian women in the fertile age group (Figs 2 & 3). We used a parametric transformation (Fig 3). Our results point to a strong negative correlation between circulating AMH and age where \( r_S = -0.528 \). The highest average AMH was in the group of women aged less than 20 years (Fig 4). This relationship has been tackled in several
A study was conducted in 2011 on a large scale of 9,601 females to describe the decline in AMH levels with age in the United Kingdom. The study was conducted on 4,590 women, then validated in 4,588 women and finally validated on 423 women known to be ovulating, aged 25–45 years. They developed a nomogram based on AMH and age and used 5 regression models: linear, biphasic, differential, power and quadratic. For each model, the mean, standard deviation (SD), median, quartiles, and range of residuals are reported, as well as the sum of absolute and squared residuals and $R^2$ statistic (proportion of variance explained by the model). $R^2$ values ranged from 19.45% to 19.48% in the training dataset and from 21.30% to 21.36% in the validation dataset, suggesting very little difference in goodness of fit. They concluded that four nonlinear regression models (esp power and quadratic model) provide the best fit. Although their work used a much larger sample size, our study cover a larger age range in the reproductive years of females (15–49 years), yet we found a stronger relationship with age. Also, our fully automated AMH assay method shows a

![Fig 5. Nomogram of age-related profile of Antimullerian hormone (AMH).](https://doi.org/10.1371/journal.pone.0254858.g005)

Table 1. Reference intervals of AMH determined for every 5 years of age from 16 to 49.

| Age   | Mid-Age | n  | LL  | Me  | UL  |
|-------|---------|----|-----|-----|-----|
| 15–19 | 17      | 27 | 0.51| 3.53| 10.4|
| 20–24 | 22      | 113| 0.08| 3.00| 12.4|
| 25–29 | 27      | 192| 0.08| 2.80| 11.6|
| 30–34 | 32      | 195| 0.02| 1.88| 8.6 |
| 35–39 | 37      | 164| 0.00| 1.13| 6.4 |
| 40–44 | 42      | 109| 0.00| 0.51| 3.4 |
| 45–49 | 47      | 42 | 0.00| 0.14| 1.4 |

LL = lower limit; Me = median; UL = upper limit.

https://doi.org/10.1371/journal.pone.0254858.t001
superior performance with excellent precision and sensitivity; i.e., intra-assay and inter-assay CVs of 1.7% and 3.5%, respectively, at mid-normal level, and the limit of quantitation of 0.01 pmol/L. Whereas intra-assay CVs at the low, mid, and high concentration levels of the method used in the UK study were 3.4%, 6.3%, and 8.6%, and inter-assay CVs were 11.4%, 8.4%, and 15.4%, and the lower limit of detection was 0.2 pmol/L. Kelsey et al also described a validated model of AMH decline from conception to menopause. Their model was generated from a study of 3,620 healthy subjects from preterm infants to 54.3 years of age. Their model has an R² of 0.34 with coverage of much wider age-range [12].

De Vet et al found that AMH peaks around the age of 20 years then declines [13]. The finding of the report agrees with our data of the highest average AMH in the group of women aged less than 20 years. While other studies report that serum AMH peaks at the age of 25 [14]. A recent study shows that AMH measured by Roche Elecsys highly correlated with antral follicle count and retrieved oocyte count after ovarian stimulation. Roche Elecsys AMH assay is traceable to the Beckman Coulter AMH Gen II ELISA (unmodified version without predilution) assay [15]. The different assay principle and reagents used in the measurement should account for a considerable part of the conflict between results of different studies over the years. Thus, the call for harmonization of AMH assays is on the rise which should reduce bias and facilitate the comparison of results [16].

The utility of AMH testing in assisted reproduction is widely discussed in the recent years. Firm evidence points to a linear correlation between serum AMH and oocyte yield. Serum AMH was suggested as the best marker to predict poor or hyper responders. Thus, integration of serum AMH in nomograms to optimize the ovarian stimulation protocol was suggested in order to reduce the risk of cycle cancelation or ovarian hyperstimulation [17].

Given that our source of data were laboratory results, the only possible source of selection bias in this work may be that the females participating in this study were seeking medical assistance and laboratory service, hence they may not be healthy women. Yet we largely overcame this issue through exclusion of cases using the questionnaire where medical history or other laboratory tests show signs of infertility or polycystic ovary syndrome. Participants were studied cases by case to exclude women who had missing data or unclear responses to the questionnaire. Cases of infertility were included only if the reason was male infertility. In PCOS, there is an increase in the number of preantral follicles [18]. Furthermore, AMH production is increased in anovulatory PCOS women by granulosa cells [19], resulting in increased plasma AMH levels in PCOS [20, 21]. Frank symptomatic polycystic syndrome was deliberately excluded in this study. However, asymptomatic ovulating polycystic ovary cases were not excluded as they exist in a small fraction of the fertile Egyptian female population.

Two recent studies suggest inter and intracycle variations during ovarian stimulation might be explained by factors other than analytical variability. AMH levels were higher in the follicular phase than the luteal phase [22]. The average intra-individual AMH variability in a menstrual cycle was 20% and this biological variation was at least twice the analytical variation (Hadlow et al., 2016) [23]. Short-term inter-cycle variation might be due to the biological variation in the number of AMH-producing follicles per cycle [24].

We demonstrate in a large cohort of Egyptian females that the circulating AMH concentrations exhibit a decline with age that is well modeled. Further validation in a similar population with clinically proven fertility and phenotyping will provide further confirmation.

To our knowledge, this is the first study to confirm age-related AMH reference intervals specific to Egyptian females in the fertile age group. Our results emphasized the strong negative correlation of AMH with age in fertile Egyptian females, introducing this nomogram in clinical practice would guarantee better assessment of fertility and ovarian reserve in different age groups of Egyptian females with their specific genetic, nutritional, and environmental profiles.
Compared to previous studies, fully automated AMH assay method shows a superior performance whether in precision or sensitivity. Our new scheme of determining the reference intervals and delineation of age-related profile (nomogram) using the power transformation of AMH values is considered a much-improved approach. In previous studies, the nomograms were constructed by non-linear regression analysis of the observed age-AMH curve. Although appropriate fitting of the curve to the entire age range was difficult, our new scheme worked well to delineate the profile for the required wide age range.

Finally, adjusting the scale of the AMH axis in our nomogram to fit our AMH transformation, would make it possible to directly deduce the AMH reference interval for any age without the need for any post-calculations, which would certainly improve its usability.

Supporting information

S1 File. (XLSX)

Author Contributions

Conceptualization: Eman Ahmed El-Attar, Tamer A. Hosny, Rania N. Bedair.

Data curation: Eman Ahmed El-Attar, Rania N. Bedair.

Formal analysis: Eman Ahmed El-Attar, Kiyoshi Ichihara, Ahmed Salah El-Din Tork.

Investigation: Eman Ahmed El-Attar.

Methodology: Tamer A. Hosny.

Project administration: Eman Ahmed El-Attar.

Software: Kiyoshi Ichihara.

Supervision: Eman Ahmed El-Attar, Tamer A. Hosny.

Validation: Ahmed Salah El-Din Tork.

Writing – original draft: Eman Ahmed El-Attar.

Writing – review & editing: Eman Ahmed El-Attar, Tamer A. Hosny, Kiyoshi Ichihara, Rania N. Bedair, Ahmed Salah El-Din Tork.

References

1. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12:685–718. https://doi.org/10.1093/humupd/dml034 PMID: 16891297

2. van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BCet al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010; 25:221–227. https://doi.org/10.1093/humrep/dep366 PMID: 19840990

3. Robertson DM, Hale GE, Fraser IS, Hughes CL, Burger HG. A proposed classification system for menstrual cycles in the menopause transition based on changes in serum hormone profiles. Menopause 2008; 15:1139–1144. https://doi.org/10.1097/gme.0b013e3181735687 PMID: 18779761

4. Kim C, Slaughter JC, Wang ET, Appiah D, Schreiner P, Leader B et al. Anti-Müllerian hormone, follicle stimulating hormone, antral follicle count, and risk of menopause within 5 years. Maturitas 2017; 102:18–25. https://doi.org/10.1016/j.maturitas.2017.04.018 PMID: 28610678

5. La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf) 2006; 64:603–610. https://doi.org/10.1111/j.1365-2265.2006.02533.x PMID: 16712660
6. Streuli I, Fraisse T, Pilet C, Ibecheole V, Bischof P, de Ziegler D. Serum anti-müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008; 90:395–400. https://doi.org/10.1016/j.fertstert.2007.06.023 PMID: 17919608

7. Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa Set al. Clinical application of serum anti-Müllerian hormone as an ovarian reserve marker: A review of recent studies. J Obstet Gynaecol Res 2018; 44:998–1006. https://doi.org/10.1111/jog.13633 PMID: 29517134

8. Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020 Nov 1; 105(11):3361–73. https://doi.org/10.1210/clinem/dgaa513 PMID: 32770239; PMCID: PMC7486884 https://doi.org/10.1210/clinem/dgaa513

9. Capuzzo M and La Marca A (2021). Use of AMH in the Differential Diagnosis of Anovulatory Disorders Including PCOS. Front. Endocrinol. 2021; 11:616766. https://doi.org/10.3389/fendo.2020.616766

10. Nelson SM, Messow MC, Wallace AM, Fleming R, McConachie A. Nomogram for the decline in serum anti-Müllerian hormone: a population study of 9,601 infertility patients. Fertil Steril 2011; 95:736–41. e1,3. https://doi.org/10.1016/j.fertster.2010.08.022 PMID: 20869051

11. Solberg HE. Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987; 25:645–656. https://doi.org/10.1006/jccl.1987.0070

12. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WHB. A validated model of serum anti-Müllerian hormone from conception to menopause. PLoS One 2011; 6:e22024. https://doi.org/10.1371/journal.pone.0022024 PMID: 2179206

13. de Vet A, Laven JS, Jong FH, Themmen APN, Fauser BCJM. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002; 77:357–362. https://doi.org/10.1016/s0015-0282(01)02993-4 PMID: 11821097

14. Anderson RA, Nelson SM, Wallace WH. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 2012; 71:28–33. https://doi.org/10.1016/j.maturitas.2011.11.008 PMID: 22119275

15. Tan EC, Chincholkar P, Su LY, Lim SL, Renuka R, Yong Ttet al. Comparison of Automated Anti-Müllerian Hormone Assays and Antral Follicle Count in Predicting Ovarian Response During Ovarian Stimulation. Fertil Reproduction Vol. 2019; 01:99–105. https://doi.org/10.1142/S2661318219500099

16. Ferguson JM, Pépin D, Duru C, Matejtschuk P, Donahoe PK, Burns CJ. Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone. Reprod Biomed Online 2018; 37:631–640. https://doi.org/10.1016/j.rbmo.2018.08.012 PMID: 30241771

17. Nyboe Andersen A, Nelson SM, Fauser BC, García-Velasco JA, Klein BM, Arce JC, et al ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 2017; 107:387–396. e4. https://doi.org/10.1016/j.fertster.2016.10.033 PMID: 27912901

18. Maciel GAR, Baracat EC, Benda JA, Markham SM, Hensing er K, Chang RJ et al. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:5321–5327. https://doi.org/10.1210/jc.2004-0643 PMID: 15531477

19. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead Set al. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007; 92:240–245. https://doi.org/10.1210/jc.2006-1582 PMID: 17062765

20. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89:318–323. https://doi.org/10.1210/jc.2003-030932 PMID: 14715867

21. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20:1820–1826. https://doi.org/10.1093/humrep/deh850 PMID: 15802325

22. Gorkem U, Kucuklier FK, Togrul C, Gungor T. Anti-Müllerian hormone exhibits a great variation in infertile women with different ovarian reserve patterns. Aust N Z J Obstet Gynaecol 2017; 57:464–468. https://doi.org/10.1111/ajno.12625 PMID: 28419409

23. Hadlow N, Brown SJ, Habib A, Wardrop R, Joseph J, Gillett M, et al. Quantifying the intraindividual variation of antimiillerian hormone in the ovarian cycle. Fertil Steril 2016; 106:1230–1237. https://doi.org/10.1016/j.fertster.2016.06.009 PMID: 27351446

24. Rombauts L, Lambalk CB, Schultz-Mosgau A, van Kuijk J, Verweij P, Gates Det al. Inter-cycle variability of the ovarian response in patients undergoing repeated stimulation with conifollitropin alfa in a gonadotropin-releasing hormone antagonist protocol. Fertil Steril 2015; 104:884–890.e2. https://doi.org/10.1016/j.fertster.2015.06.027 PMID: 26187300